Dr. Monica Mirela Mita, MD

Dr. Mita practices at Hoag Hospital Newport Beach in Newport Beach, California, part of Hoag Memorial Hospital Presbyterian.

Dr. Mita's NPI, 1760450043, was assigned on March 10, 2006. Dr. Mita graduated from Carol Davila University of Medicine and Pharmacy in 1992. Dr. Mita's Texas license number on file is M3029.

Dr. Mita's primary practice is Hoag Hospital Newport Beach, at One Hoag Drive, Newport Beach, CA 92663 in Orange County. The practice phone is (949) 764-4624. Dr. Mita also practices at Hoag Hospital Newport Beach, 1 Hoag Dr, Newport Beach, CA 92663.

Dr. Mita's primary practice is Hoag Hospital Newport Beach in Newport Beach, California, part of Hoag Memorial Hospital Presbyterian. Dr. Mita is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Hoag Clinic. Dmand AI also links Dr. Mita to 1 more hospital and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mita practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Mita's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Mita's licenses on file in 3 states: Texas, California and Alabama.

Dmand AI lists breast cancer among the conditions Dr. Mita treats.

CMS data shows 372 Medicare services from Dr. Mita across 5 procedure codes in 2024, for 164 Medicare patients. Medicare paid $31,361 for them.

CMS counts 164 Medicare patients who saw Dr. Mita in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have cancer, and 73% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.31, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mita's median patient age at 69, with 96% women.

In 2024, Dr. Mita wrote 440 Medicare Part D claims for 131 patients. 95% of them were for generic drugs. CMS names the drug for 337 of them, across 10 drugs with 11 or more claims each, at $6,238 in total drug cost. In 2023, CMS named 466 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Mita for performance year 2024, reported as part of a group. Dr. Mita accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mita as offering telehealth.

Dmand AI links 137 papers to Dr. Mita, published from 2007 to 2024. 2014 was the busiest year, with 10. The most frequent topics are Antineoplastic Agents, Maximum Tolerated Dose and Antineoplastic Combined Chemotherapy Protocols. Dr. Mita has published most often in Clin Cancer Res. Dr. Mita's most frequent co-authors are Alain Catalin Mita, MD, John Sarantopoulos, MD and Anthony W. Tolcher.

Dmand AI links Dr. Mita to 29 clinical trials, 15 of them phase 1 studies. 11 are still active or recruiting. Conditions studied include Breast Neoplasms, Neoplasm Metastasis and Breast Diseases. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Mita that name 2 trials.

CMS Open Payments shows 61 general payments to Dr. Mita from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Sanofi and Genzyme US Companies paid the most, $8,979. It also lists 9 research payments totaling $10,053 from 2016 to 2024, naming 2 clinical trials.

Dr. Mita graduated from Carol Davila University of Medicine and Pharmacy in 1992. Dr. Mita is a member of ASCO.

Dr. Mita is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.